This review highlights the limitations of existing antithrombotic therapies in ACS and discusses the potential of emerging oral direct thrombin inhibitors like ximelagatran.
No takes yet. Share an insight, caveat, or question.
No practice change warranted in ACS; leaves open whether oral direct thrombin inhibitors can address current limitations.
Elliot M. Antman (2004) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: